公开(公告)号：CA2950415A1

公开(公告)日：2015-12-03

申请号：CA2950415

申请日：2015-05-27

Applicant: ACADEMIA SINICA

Inventor： WONG CHI-HUEY ,  WU CHUNG-YI ,  TSAI MING-HUNG

IPC: C07K16/00

Abstract: The present disclosure relates to a novel class of anti-CD20 monoclonal antibodies comprising a homogeneous population of anti-CD20 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-CD20 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.

公开(公告)号：AU2015267047A1

公开(公告)日：2017-01-05

申请号：AU2015267047

申请日：2015-05-27

Applicant: ACADEMIA SINICA

Inventor： WU CHUNG-YI ,  TSAI MING-HUNG ,  WONG CHI-HUEY

IPC: C07K16/00

Abstract: The present disclosure relates to a novel class of anti-CD20 monoclonal antibodies comprising a homogeneous population of anti-CD20 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-CD20 monoclonal antibodies by Fc glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased Fc receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.

公开(公告)号：AU2021200784A1

公开(公告)日：2021-03-04

申请号：AU2021200784

申请日：2021-02-08

Applicant: ACADEMIA SINICA

Inventor： WU CHUNG-YI ,  TSAI MING-HUNG ,  WONG CHI-HUEY

IPC: C07K16/00

Abstract: The present disclosure relates to a novel class of anti-CD20 monoclonal antibodies comprising a homogeneous population of anti-CD20 IgG molecules having the same N-glycan on each of Fc. The antibodies of the invention can be produced from anti-CD20 monoclonal antibodies by FE glycoengineering. Importantly, the antibodies of the invention have improved therapeutic values with increased ADCC activity and increased FE receptor binding affinity compared to the corresponding monoclonal antibodies that have not been glycoengineered.